AgreenSkills
Pathways for inventive researchers

APPLICATION ID: 492

Curriculum Vitae

Personal information

First name / Surname	**Mohammed Akli AYOUB**
Address(es)	King Saud University, College of Science, Department of Biochemistry PO Box 2455, Riyadh 11451 - Kingdom of Saudi Arabia
Telephone	
Mobile	
E-mail	mayoub@ksu.edu.sa – ayoubmohamed@yahoo.fr – ayoub.mohammed.akli@gmail.com
Nationality	French
Date of birth	
Gender	Male

Personal statement and statement of intent	My scientific career has two major research axes: (i) the biology and pharmacology of cell surface receptors and (ii) technology development and innovation. In particular, I have been instrumental in the development of bioluminescence and time resolved-fluorescence resonance energy transfer (BRET and TR-FRET) technologies and their multiple applications to study cell surface receptors including G protein-coupled receptors (GPCRs) and receptor tyrosine kinase (RTKs). During my scientific career I have published more than 30 original articles and one book chapter mostly dealing with the application of BRET and TR-FRET technologies to study different aspects of GPCRs but also TKRs such as the profiling of receptor complexes and their dynamics, association with signalling proteins, drug binding and receptor regulation. **The impact of my work is nicely illustrated by the total of 1325 citations** *(according to Scopus up to 24 March 2014)*. Many laboratories have sought my expertise in the application of these technologies to study the formation and functioning of GPCR and TKR complexes as well as other examples of protein-protein interactions. This has resulted in my contribution to numerous publications where I planned and/or carried out the BRET experiments and the related pharmacological assays. Also, I have been acknowledged in more than 10 scientific publications for technical advice and consulting on GPCRs and BRET studies. My work on the oligomerization of melatonin receptors published in 2002 was one of the world's first studies demonstrating GPCR oligomerization using BRET receiving more than **190 citations**. Moreover, in 2007 and 2010 I published two seminal works supporting the concept of receptor-G protein pre-assembly and agonist-induced conformational changes within GPCR-G protein complexes using a combination of BRET and TR-FRET. Up to now, I have always focused my research

	interest and career plans on the development of BRET/TR-FRET-based assays to study the different aspects of GPCRs but also TKRs. I am highly motivated at pursuing my research in this field for the medium- and long-term future by developing and applying new tools to move further towards understanding the function of GPCRs/TKRs and their implication in human and animal physiopathologies. I have great interest in investigating these receptors in the context of the emerging concepts of cell surface receptor function and signalling such as heteromerization, receptor-G protein preassembly, biased signalling, allosteric modulation, multiple coupling, and receptor transactivation. I am convinced that nanobody-mediated targeting of GPCRs represent a powerful approach to address all these phenomena is their very molecular details while also developing novel drug candidates. All these concepts are largely covered in the project that I propose on the development of new generation of GPCR drugs based on nanobodies which deals with my fields of expertise (structure, pharmacology and signalling) as well as their implication in physiopathology. I strongly believe that with my knowledge on GPCRs, well-recognized expertise in BRET/TR-FRET technologies, leadership and international collaboration network, I can play a pivotal role for the successful achievement of the proposed project. I am convinced that my mobility to the host laboratory at INRA in Tours is a key step in my career since it will definitely open me a golden opportunity to achieve my scientific goals while contributing to the new era of GPCR research and development. Indeed, I consider that the scientific environment at INRA-Tours is excellent with interesting perspectives to be expected in terms of technology development, intellectual property and economic impacts. For the long-term I propose to establish my own research group around GPCRs and the development of new drugs and technologies in the field. Also, my mobility aims to transfer my know-how to the different skills and expertise on GPCRs already established in this UMR085. For all these reasons, I truly hope that AgreenSkills will evaluate my application favourably.

Education and training

Location and dates	September 2000 – December 2003: University of Paris XI – Thesis carried out at Cochin Institute, Paris (France)
Title of qualification awarded	**PhD of Biochemistry and Molecular Biology**
Principal subjects/occupational skills covered	**Study of the dimerization of melatonin receptors using bioluminescence resonance energy transfer (BRET) technique**
Name of Institute	**University of Paris XI**
Location and dates	September 1999 – July 2000: University of Paris XI – Project carried out at Cochin Institute, Paris (France)
Title of qualification awarded	**Master of structure and functioning of the integrated biological systems**
Principal subjects/occupational skills covered	**Development of bioluminescence resonance energy transfer (BRET) technique to study protein-protein interactions**
Name of Institute	**University of Paris XI**

Work experience

Location and dates	Saudi Arabia, Riyadh: **from 21 January 2012 to 11 June 2014**
Occupation or position held	**Assistant Professor**
Main activities and responsibilities	Teaching and Co-manager of the Protein Research Chair
Name of employer	**King Saud University – College of Science - Biochemistry Department**
Location and dates	Australia, Perth: **from 17 August 2009 to 31 December 2011**
Occupation or position held	**Research Assistant Professor**
Main activities and responsibilities	Research and Master student co-supervision
Name of employer	**Western Australian Institute for Medical Research (WAIMR) and Centre for Medical Research - Laboratory of Molecular Endocrinology and GPCR**
Location and dates	France, Montpellier: **from 01 October 2004 – 31 May 2009**
Occupation or position held	**Postdoc Fellow**
Main activities and responsibilities	Research and Bachelor student supervision
Name of employer	**Institute of Functional Genomics - Department of Molecular Pharmacology - CNRS UMR 5203, INSERM U661, Universities Montpellier 1 et 2**

Languages

Mother tongue(s): Kabyle (Berber)

Other language(s)	Understanding		Speaking		Writing
European level (*)	Listening	Reading	Spoken interaction	Spoken production	
French	C2	C2	C2	C2	C2
English	C2	C2	C2	C2	C2
Arabic	C2	C2	C1	C1	B1

(*) Common European Framework of Reference for Languages
http://europass.cedefop.europa.eu/en/resources/european-language-levels-cefr

Academic Record

Publications

Accepted, in press and published articles / papers:

1. Elamin B.A, Al-Maleki A, Ismael M.A, and **Ayoub M.A***. **(2014)** *Purification and Functional Characterization of Pancreatic Insulin From Camel (Camelus dromedaries)*. ***Saudi Journal of Biological Sciences (In press).***

2. **Ayoub M.A***. **(2014)** *The Couple G Protein-Coupled Receptor-G Protein: Preassembly versus Agonist-Induced Interaction*. ***Receptors & Clinical Investigation 1(3):64-67***.

3. **Ayoub M.A*** and Pin J.P. **(2013)** *Interaction of Protease-Activated Receptor 2 with G Proteins and β-arrestin 1 Studied by Bioluminescence Resonance Energy*

Transfer. ***Frontiers in Molecular and Structural Endocrinology*** 4:196. doi: 10.3389/fendo.2013.00196.

4. **Ayoub M.A***. **(2013)** *The Nobel Prize in Chemistry 2012, G Protein-Coupled Receptors, Rightly Rewarded.* ***Arabian Journal of Chemistry*** doi: http://dx.doi.org/10.1016/j.arabjc.2013.08.020. ***(Impact factor: 2.27)***

5. Armstrong S.P, Seeber R.M, **Ayoub M.A**, Feldman B.J, and Pfleger K.D.G. **(2013)** *Characterization of Three Vasopressin Receptor 2 Variants: An Apparent Polymorphism (V266A) and Two Loss-of-Function Mutations (R181C and M311V)*. ***PLoS ONE*** 8(6): e65885. ***(Impact factor: 3.73)***

6. **Ayoub M.A**, See H.B, Seeber R.M, Armstrong S.P, and Pfleger K.D.G. **(2013)** *Profiling Epidermal Growth Factor Receptor and Heregulin Receptor 3 Heteromerization Using Receptor Tyrosine Kinase Heteromer Investigation Technology.* ***PLoS ONE*** 8(5): e64672. ***(Impact factor: 3.73)***

7. **Ayoub M.A,** Al-Senaidy A, and Pin J.P. **(2012)** *Receptor-G Protein Interaction Studied by Bioluminescence Resonance Energy Transfer: Lessons From Protease-Activated Receptor 1*. ***Frontiers in Molecular and Structural Endocrinology*** 3: 82. ***(citations: 5)***

8. Brown R.M, Mustafa S, **Ayoub M.A,** Dodd P.R**,** Pfleger K.D.G, and Lawrence A.J. **(2012)** *mGlu5 receptor functional interactions and addiction.* ***Frontiers in Pharmacology*** 3: 84. ***(citations: 3)***

9. Mustafa S, See H.B, Seeber R.M, Armstrong S.P, White C.W, Ventura S, **Ayoub M.A,** and Pfleger K.D.G. **(2012)** *Identification and profiling of a novel α1A-adrenoceptor-CXC chemokine receptor 2 heteromer.* ***The Journal of Biological Chemistry*** 287(16): 12952-12965. ***(Impact factor: 4.65, citations: 11)***

10. **Ayoub M.A#,** Angelicheva D#, Vile D, Chandler D, Morar B, Cavanaugh J.A, Visscher P.M, Jablensky A, Pfleger K.D.G, and Kalaydjieva L. **(2012)** *Deleterious GRM1 Mutations in Schizophrenia.* ***PLoS ONE*** 7(3): e32849. ***(Impact factor: 3.73, citations: 3)***

11. Tallet E, Fernandez I, Zhang C, Salsac M, Gregor N, **Ayoub M.A**, Pin J.P, Trinquet E, and Goffin V. **(2011)** *Investigation of Prolactin Receptor Activation and Blockade Using Time-Resolved Fluorescence Resonance Energy Transfer*. ***Frontiers in Cellular Endocrinology*** 2: 29. ***(citations: 2)***

12. Mustafa S, **Ayoub M.A,** and Pfleger K.D. **(2010)** *Uncovering GPCR heteromer-biased ligands*. ***Drug Discovery Today: Technologies*** 7(1): e77-e85 ***(citations: 8)***

13. **Ayoub M.A**, Trinquet E, Pfleger K.D.G, and Pin J.P. **(2010)** *Differential association modes of the thrombin receptor PAR1 with Gαi1, Gα12 and β-arrestin 1*. ***The FASEB Journal*** 24(9): 3522-3535. ***(Impact factor: 5.70, citations: 18)***

14. **Ayoub M.A** and Pfleger K.D.G. **(2010)** *Recent advances in bioluminescence resonance energy transfer technologies to study GPCR heteromerization*. ***Current Opinion in Pharmacology*** 10(1): 44-52. ***(Impact factor: 5.44, citations: 45)***

15. Tenenbaum J#, **Ayoub M.A#**, Perkovska S, Adra-Delenne A.L, Mendre C, Ranchin B,

Bricca G, Geelen G, Mouillac B, Durroux T, and Morin M. **(2009)** *The constitutively active V2 receptor mutants conferring NSIAD are weakly sensitive to agonist and antagonist regulation*. ***PLoS ONE*** 4(12): e8383. ***(Impact factor: 3.73, citations: 9)***

16. **Ayoub M.A**[#], Damian M[#], Gespach C, Ferrandis E, Lavergne O, De Wever O, Banères J.L, Pin J.P, and Prévost G.P. **(2009)** *Inhibition of Heterotrimeric G Protein Signaling by a Small Molecule Acting on Galpha Subunit.* ***The Journal of Biological Chemistry*** 284(42): 29136-29145. ***(Impact factor: 4.65, citations: 20)***

17. Rives M.L, Vol C, Fukazawa Y, Tinel N, Trinquet E, **Ayoub M.A**, Shigemoto R, Pin J.P, and Prézeau L. **(2009)** *Cross-talk between GABAB and mGlu1a receptors reveals new insight into GPCR signal integration.* ***The EMBO Journal*** 8(15): 2195-2208. ***(Impact factor: 9.82, citations: 50)***

18. Maurel D, Comps-Agrar L, Brock C, Rives M.L, Bourrier E, **Ayoub M.A**, Bazin H, Tinel N, Durroux T, Prézeau L, Trinquet E, and Pin J.P. **(2008)** *Cell surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization*. ***Nature Methods*** 5(6): 561-567. ***(Impact factor: 23.56, citations: 218)***

19. Berthouze M, Rivail L, Lucas A, **Ayoub M.A**, Russo O, Sicsic S, Fischmeister R, Berque-Bestel I, Jockers R, and Lezoualc'h F. **(2007)** *Two Transmembrane Cys Residues are Involved in 5-HT4 Receptor Dimerisation.* ***Biochem Biophys Res Commun*** 356(3): 642-647. ***(Impact factor: 2.40, citations: 32)***

20. **Ayoub M.A**, Maurel D, Binet V, Fink M, Prézeau L, Ansanay H, and Pin J.P. **(2007)** *Real-time analysis of agonist-induced activation of Protease-activated receptor 1/Gαi1 protein complex measured by BRET in living cells.* ***Molecular Pharmacology*** 71(5): 1329-1340. ***(Impact factor: 4.41, citations: 47)***

21. Savaskan E, Jockers R, **Ayoub M.A**, Angeloni D, Fraschini F, Flammer J, Eckert A, Müller-Spahn F, and Meyer P. **(2007)** *The MT2 Melatonin Receptor Subtype is Present in Human Retina and Decreases in Alzheimer's Disease.* ***Current Alzheimer Research*** 4(1): 47-51. ***(Impact factor: 3.68, citations: 25)***

22. Levoye A, Dam J, **Ayoub M.A**, Guillaume J.L, and Jockers R. **(2006)** *Do orphan G protein-coupled receptors have ligand-independent functions? New insights from receptor heterodimers*. ***EMBO Report*** 7(11): 1094-1098. ***(Impact factor: 7.19, citations: 59)***

23. Levoye A, Dam J, **Ayoub M.A**, Guillaume J.L, Couturier C, Delagrange P, and Jockers R. **(2006)** *The orphan GPR50 receptor specifically antagonizes MT1 melatonin receptor function through heterodimerization*. ***The EMBO Journal*** 25(13): 3012-23. ***(Impact factor: 9.82, citations: 129)***

24. Levoye L, Jockers R, **Ayoub M.A**, Delagrange P, Savaskan E, and Guillaume J.L. **(2006)** *Are G protein-coupled receptor heterodimers of physiological relevance? – Focus on melatonin receptors*. ***Chronobiology International*** 23(1-2): 419-26. ***(Impact factor: 4.35, citations: 32)***

25. Berthouze M, **Ayoub M.A**, Russo O, Rivail L, Sicsic S, Fischmeister R, Berque-Bestel I, Jockers R, and Lezoualc'h F. **(2005)** *Constitutive Dimerization of Human Serotonin 5-HT4 Receptors in Living Cells.* ***FEBS Letters*** 579(14): 2973-2980. ***(Impact factor: 3.58, citations: 31)***

	26. Savaskan E, **Ayoub M.A**, Ravid R, Angeloni D, Fraschini F, Meier F, Eckert A, Müller-Spahn F, and Jockers R. **(2005)** *Reduced Hippocampal MT2 Melatonin Receptor Expression in Alzheimer's Disease*. ***Journal of Pineal Research*** 38(1): 10-16. ***(Impact factor: 7.30, citations: 90)*** 27. **Ayoub M.A**, Levoye A, Delagrange P, and Jockers R. **(2004)** *Preferential Formation of MT1/MT2 Melatonin Receptor Heterodimers With Distinct Ligand Interaction Properties Compared With MT2 Homodimers.* ***Molecular Pharmacology*** 66(2): 312-321. ***(Impact factor: 4.41, citations: 96)*** 28. Terrillon S, Durroux T, Mouillac B, Breit A, **Ayoub M.A**, Taulan M, Jockers R, Barberis C, and Bouvier M. **(2003)** *Oxytocin and Vasopressin V1a, and V2 Receptors Form Constitutive Homo- and Hetero-dimers during Biosynthesis*. ***Molecular Endocrinology*** 17(4): 677-691. ***(Impact factor: 4.75, citations: 196)*** 29. Couturier C, **Ayoub M.A**, and Jockers R. **(2002)** *BRET ermÖglicht die Messung von protein-Interaktionen in lebenden Zellen*. ***BIOspektrum*** 5; 612-614. 30. **Ayoub M.A**, Couturier C, Lucas-Meunier E, Angers S, Fossier P, Bouvier M, and Jockers R. **(2002)** *Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer*. ***The Journal of Biological Chemistry*** 277(24): 21522-21528***. (Impact factor: 4.65, citations: 193)*** ****Corresponding author*** ***# Authors equally contributed***
	Submitted publications:
	1. **Ayoub M.A#**, Zhang Y#, Kelly, R.S, See H.B, Johnstone, E.K.M, McCall E, Williams J, Kelly D.J, and Pfleger K.D.G. Functional interaction between angiotensin II receptor and CC chemokine receptor 2 and its implication in Chronic Kidney Disease. ***Submitted to Endocrinology (Impact factor: 4.717).*** 2. **Ayoub M.A***, Trebaux J, Charrier-Savournin F, Moya A.G, Pin J.P, Pfleger K.D.G, and Trinquet E. Homogeneous Time-Resolved Fluorescence-Based Assay to Monitor Extracellular Signal-Regulated Kinase Signalling in a High-Throughput Format. ***Submitted to BioTechniques (Impact factor: 2.399)*** 3. Alharbi I.A, Khan M, Rabbani N, Al-Senaidy A.M, Ismael M.A, and **Ayoub M.A***. Inhibition of NAPDH: Quinone Oxidoreductase Activity of Camel Lens ζ-Crystallin by Colchicine. ***Submitted to Arabian Journal of Chemistry (Impact factor: 2.27).*** ****Corresponding author*** ***# Authors equally contributed*** ***Citation report according to Scopus on 24 March 2014***
Presentations as invited speaker	**1.** *Homo- and hetero-oligomerization of melatonin receptors – effects of ligand binding monitored by Bioluminescence Resonance Energy Transfer (BRET).* The XIth European Pineal and Biological Rhythms Society Symposium, **18-23 July 2002 - Aberdeen, Scotland.** **2.** *Study of the dimerization and conformational changes of melatonin receptors by BRET*. Seminar of the Department of Biochemistry, **8 March 2004 - University of Paris Sud XI, France.**

	3. *Study of the dimerization and conformational changes of melatonin receptors by BRET*. Invited by CisBio Bioassays, **15 April 2004 – Bagnol sur Ceze, France.** **4.** *BRET to detect conformational changes and measure protein-protein interactions*. Meeting of IFR3 – Molecular Pharmacology Plate-Forme, **16 March 2006 – Montpellier, France.** **5.** *Monitoring of the coupling of protease-activated receptors to Gαi1 by BRET*. European STREP - Functional Pharmacogenomics of GPCRs, **19 April 2006 – Montpellier, France.** **6.** *Towards understanding the molecular basis for multiple G protein coupling of GPCRs.* Seminar of the Western Australian Institute for Medical Research (WAIMR), **24 March 2010 – Perth, Australia**. **7.** *Time-resolved FRET to study GPCRs* – BMG Labtech Technology Workshops. The VIth annual meeting of the Molecular Pharmacology of G Protein-Coupled Receptors. **2-4 December 2010 - Melbourne, Australia.** **8.** *Evaluation of PerkinElmer LANCE Ultra cAMP kit* – PerkinElmer Technology Workshops. The VIth annual meeting of the Molecular Pharmacology of G Protein-Coupled Receptors. **2-4 December 2010 - Melbourne, Australia.** **9.** *Bioluminescence Resonance Energy Transfer Technology to Study Protein-Protein Interactions In Live Cells*. Seminar of the Department of Biochemistry – College of Science, University of King Saud. **29 April 2012 - Riyadh, Kingdom of Saudi Arabia.** **10.** *Receptor Tyrosine Kinase Heteromer Investigation Technology (RTK-HIT)*. Seminar of the Protein Research Chair - Department of Biochemistry – College of Science, University of King Saud. **08 May 2013 - Riyadh, Kingdom of Saudi Arabia.**
Books or books chapter author	**1.** Pin J.P, **Ayoub M.A**, Maurel D, Perroy J, and Trinquet E. **(2008)** *Energy Transfer Technologies to Monitor the Dynamics and Signaling Properties of G-Protein Coupled Receptors in Living Cells.* **Biophysical Analysis of Membrane Proteins** - ***Investigating Structure and Function*** (edited by E. Pebay-Peyroula), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. doi: 10.1002/9783527621224.ch13 - Chapter 13, Part VI, 311-334. ***(citations: 3)***
Participation in open calls for proposals as contributor or leader	**1.** Discovery project grant of the **Australian Research Council (ARC)**. Funding period: **2012-2014** - Reference: **DP120101297 –** Grant Amount: **AUD 270,000.** Project title: ***Investigating the functional interaction between vasopressin and angiotensin receptors*.** Investigators and Partners: Associate Professor Pfleger Kevin (Chief Investigator 1, CI1), **Dr. Mohammed Akli Ayoub (CI2)**, Professor Kelly Darren (CI3), and Dr. Durroux Thierry (Partner Investigator, PI). **2.** Research Group Grant Call from the **Deanship of Scientific Research** – King Saud University - Riyadh, Kingdom of Saudi Arabia. Funding period: **2013-2014** – Reference: **RGP-VPP-286** – Grant amount: **SAR 150,000.** Investigators and Partners: **Dr. Mohammed Akli Ayoub (PI)** and Dr. Khaled Al-Hosaini (Co-investigator).

	3. Technology and Innovation Plan – Medical and Health Strategic Priorities, King Abdulaziz City of Science and Technology - Riyadh, Kingdom of Saudi Arabia. Funding period: **2013-2015** – Reference: **13-MED899-02** – Grant amount: **SAR 1,800,000.** Project title: ***Identification and Pharmacological Profiling of the Anti-Diabetic Agent(s) in Camel Milk and Molecular Characterization of Insulin Resistance in the Arabian Camel*.** Investigators and Partners: **Dr. Mohammed Akli Ayoub (PI),** Dr. Abdulrahman Al-Senaidy (Co-I1), Dr. Khaled Al-Hosaini (Co-I2), Dr. Mohamed Al-Fageeh (Co-I3), and Dr. Tarik Issad (International Consultant from Cochin Institute - Paris, France).
Awards and prizes, if any	**1.** Naturalia & Biologia travel award to attend the XXXIVth Congress of the International Union of Physiological Sciences. 21-23 August 2001 - **Adelaide, Australia.** **2.** The XIth European Pineal and Biological Rhythms Society Symposium: 18-23 July 2002 - **Aberdeen, Scotland**. **3.** Travel Award of "The Gordon Conference – Molecular Pharmacology": 31 May- 5 June 2009 - **Il Ciocco, Lucca, Italy**. **4.** The Supplementary Travel Grant of the University of Western Australia to support my participation to "The VIth Annual Meeting of the Molecular Pharmacology of G Protein-Coupled Receptors": 2-4 December 2010 - **Melbourne, Australia.** **5.** The International Meeting Travel Grant of King Saud University to attend "The Gordon Conference – Molecular Pharmacology". 28 April - 03 May 2013 - **Il Ciocco, Lucca, Italy.**

Collaboration and Networking

Partnerships or experience with industry	**1. Servier Laboratories, France (2000-2003)** during my PhD for all my work on Melatonin receptors. **2. CisBio Bioassay, France (2004-2009)** during my postdoc for BRET and TR-FRET development and application to study GPCRs. **3. IPSEN, France (2008-2009)** for the characterization of the anti-tumor compound BIM-46187. **4. Dimerix Bioscience Pty Ltd, Australia (2009-2011)** during my research position at WAIMR for my project on the study of GPCR complexes. **5. Oncology Research International, and TransBio, Australia (2010-2011)** during my research position at WAIMR for the application of GPCR-HIT technology to study receptor complexes. **6. BMG Labtech, Australia (2010):** Comparative study on different plate readers (PHERAStar FS, POLARStar Omega, Mithras LB940, Envision) using both BRET and TR-FRET.
Graduate teaching as lecturer or training coordinator	Department of Biochemistry, College of Science, King Saud University - Riyadh, Kingdom of Saudi Arabia. **1. Bachelor Courses:** Biomembranes and Cell Signaling (BCH 452) Hormones (BCH 453) Research and Seminar (BCH 497)

	2. Master Courses: Selected topics in Biochemistry (BCH 590) Biochemical Endocrinology (BCH 560)
Membership of professional bodies and committees	**Editorial Board:** Frontiers in Molecular and Structural Endocrinology. **2012/2014:** Member of the Committee of Graduate Studies and Research - Department of Biochemistry, College of Science, King Saud University. **2012/2013:** Member of the Technical Committee of the Central Laboratory - College of Science, King Saud University.

Research management, Technology transfer, and Communication

Team management	**2012-2014:** Co-management of the **Protein Research Chair** - Department of Biochemistry, College of Science, King Saud University – Riyadh, Saudi Arabia.
Technological platform management	**2004-2009:** Responsible all BRET-based assays at the **ARPEGE Pharmacology Facility** at the Institute of Functional Genomics - Department of Molecular Pharmacology - CNRS UMR 5203, INSERM U661 - Montpellier, France.

Other experience and skills relevant to the application	**Peer Reviewer Activity:** **Journals:** The Journal of Biological Chemistry - ACS Chemical Biology - Current Opinion in Pharmacology - Molecular Pharmacology - Frontiers in Cellular Endocrinology - Expert Opinion on Drug Discovery - Frontiers in Molecular and Structural Endocrinology – BioTechniques - Journal of Saudi Chemical Society. **Grants:** • French National Research Agency – Neurosciences Grant 2011. • Australian Research Council – Scheme Round Discovery - Projects 2013 round 1. • Australian Research Council – ARC Future Fellowships 2013 round 1. • Australian Research Council – Scheme Round Linkage - Projects 2014 round 1. • Biotechnology and Biological Sciences Research Council 2014, United Kingdom – BBSRC Grant Reference: BB/L019418/1. **PhD and Master Thesis:** • **18 April 2013:** PhD thesis at the Department of Biological Sciences - University of Sciences and Technology Houari Boumediene, Algiers, Algeria. **"Role of Cytokines and Nitrogen Monoxide in the Immune Dysfunctions and Immunosurveillance of Patients with Behçet's Disease".** • **25 December 2013:** Master thesis in the Biochemistry Department – King Saud University, Riyadh, Saudi Arabia. **"Comparative Study of the Purification and Characterization of Peroxidase from Date Palm and Doum Palm Leaves".** • **10 April 2014:** Master thesis in the Biochemistry Department – King Saud University, Riyadh, Saudi Arabia. **"Cloning, Expression and Characterization of Glutathione Reductase from Camel Liver".**

Scientific References

Full name	**Kevin PFLEGER, PhD**
Position	Associate Professor
Institution	Harry Perkins Institute of Medical Research – University of Western Australia - Nedlands, Western Australia
Email address	**kevin.pfleger@perkins.uwa.edu.au**
Full name	**Jean-Philippe PIN, PhD**
Position	Director of Institute of Functional Genomics
Institution	Institute of Functional Genomics - Department of Molecular Pharmacology - CNRS UMR 5203, INSERM U661 - Montpellier, France
Email address	**Jean-Philippe.Pin@igf.cnrs.fr**
Full name	**Ralf JOCKERS, PhD**
Position	Director of the laboratory “Functional Pharmacology and Pathophysiology of Membrane Receptors"
Institution	Cochin Institute - INSERM U1016, CNRS 8104, Université Paris Descartes – Paris, France
Email address	**ralf.jockers@inserm.fr**

How did you find out about AgreenSkills?

	The host laboratory